BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses

Journal of Immunology

Volumn 190, Issue 7, 2013, Pages 3670-3678

  Belkina, Anna C ^a   Nikolajczyk, Barbara S ^a   Denis, Gerald V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRD4 PROTEIN; CYTOKINE; INTERLEUKIN 6; JQ 1; LIPOPOLYSACCHARIDE; PROTEIN INHIBITOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRD2 GENE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE STORM; ENDOTOXEMIA; GENE; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE SILENCING; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AZEPINES; BONE MARROW CELLS; CELL LINE; CHROMATIN; CYTOKINES; ENZYME ACTIVATION; GENE KNOCKDOWN TECHNIQUES; INFLAMMATION; INTERFERON-GAMMA; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; NF-KAPPA B; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84873256270     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202838     Document Type: Article

References (51)

1. Clapier, C. R., and B. R. Cairns. 2009. The biology of chromatin remodeling complexes. Annu. Rev. Biochem. 78: 273-304.
2. Natoli, G. 2009. Control of NF-kappaB-dependent transcriptional responses by chromatin organization. Cold Spring Harb. Perspect. Biol. 1: a000224.
3. Shahbazian, M. D., and M. Grunstein. 2007. Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem. 76: 75-100.
4. Saccani, S., S. Pantano, and G. Natoli. 2001. Two waves of nuclear factor kappaB recruitment to target promoters. J. Exp. Med. 193: 1351-1359.
5. Sullivan, K. E., A. B. M. Reddy, K. Dietzmann, A. R. Suriano, V. P. Kocieda, M. Stewart, and M. Bhatia. 2007. Epigenetic regulation of tumor necrosis factor alpha. Mol. Cell. Biol. 27: 5147-5160.
6. Dhalluin, C., J. E. Carlson, L. Zeng, C. He, A. K. Aggarwal, and M. M. Zhou. 1999. Structure and ligand of a histone acetyltransferase bromodomain. Nature 399: 491-496.
7. Owen, D. J., P. Ornaghi, J. C. Yang, N. Lowe, P. R. Evans, P. Ballario, D. Neuhaus, P. Filetici, and A. A. Travers. 2000. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J. 19: 6141-6149.
8. Sanchez, R., and M.-M. Zhou. 2009. The role of human bromodomains in chromatin biology and gene transcription. Curr. Opin. Drug Discov. Devel. 12: 659-665.
9. Filippakopoulos, P., J. Qi, S. Picaud, Y. Shen, W. B. Smith, O. Fedorov, E. M. Morse, T. Keates, T. T. Hickman, I. Felletar, et al. 2010. Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
10. Thorpe, K. L., P. Gorman, C. Thomas, D. Sheer, J. Trowsdale, and S. Beck. 1997. Chromosomal localization, gene structure and transcription pattern of the ORFX gene, a homologue of the MHC-linked RING3 gene. Gene 200: 177-183.
11. Rhee, K., M. Brunori, V. Besset, R. Trousdale, and D. J. Wolgemuth. 1998. Expression and potential role of Fsrg1, a murine bromodomain-containing homologue of the Drosophila gene female sterile homeotic. J. Cell Sci. 111: 3541-3550.
12. Dey, A., J. Ellenberg, A. Farina, A. E. Coleman, T. Maruyama, S. Sciortino, J. Lippincott-Schwartz, and K. Ozato. 2000. A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition. Mol. Cell. Biol. 20: 6537-6549.
13. Wang, F., H. Liu, W. P. Blanton, A. Belkina, N. K. Lebrasseur, and G. V. Denis. 2010. Brd2 disruption in mice causes severe obesity without Type 2 diabetes. Biochem. J. 425: 71-83.
14. Guo, N., D. V. Faller, and G. V. Denis. 2000. Activation-induced nuclear translocation of RING3. J. Cell Sci. 113: 3085-3091.
15. Denis, G. V., C. Vaziri, N. Guo, and D. V. Faller. 2000. RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. Cell Growth Differ. 11: 417-424.
16. Dey, A., F. Chitsaz, A. Abbasi, T. Misteli, and K. Ozato. 2003. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. USA 100: 8758-8763.
17. Mochizuki, K., A. Nishiyama, M. K. Jang, A. Dey, A. Ghosh, T. Tamura, H. Natsume, H. Yao, and K. Ozato. 2008. The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. J. Biol. Chem. 283: 9040-9048.
18. Sinha, A., D. V. Faller, and G. V. Denis. 2005. Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem. J. 387: 257-269.
19. Brès, V., S. M. Yoh, and K. A. Jones. 2008. The multi-tasking P-TEFb complex. Curr. Opin. Cell Biol. 20: 334-340.
20. Jang, M. K., K. Mochizuki, M. Zhou, H.-S. Jeong, J. N. Brady, and K. Ozato. 2005. The bromodomain protein Brd4 is a positive regulatory component of PTEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 19: 523-534.
21. Yang, Z., J. H. N. Yik, R. Chen, N. He, M. K. Jang, K. Ozato, and Q. Zhou. 2005. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 19: 535-545.
22. Hewings, D. S., M. Wang, M. Philpott, O. Fedorov, S. Uttarkar, P. Filippakopoulos, S. Picaud, C.Vuppusetty, B. Marsden, S. Knapp, S. J. Conway, andT. D. Heightman. 2011. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J. Med. Chem. 54: 6761-70.
23. French, C. A., C. L. Ramirez, J. Kolmakova, T. T. Hickman, M. J. Cameron, M. E. Thyne, J. L. Kutok, J. A. Toretsky, A. K. Tadavarthy, U. R. Kees, et al. 2008. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27: 2237-2242.
24. French, C. A. 2010. Demystified molecular pathology of NUT midline carcinomas. J. Clin. Pathol. 63: 492-496.
25. Delmore, J. E., G. C. Issa, M. E. Lemieux, P. B. Rahl, J. Shi, H. M. Jacobs, E. Kastritis, T. Gilpatrick, R. M. Paranal, J. Qi, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
26. Zuber, J., J. Shi, E. Wang, A. R. Rappaport, H. Herrmann, E. A. Sison, D. Magoon, J. Qi, K. Blatt, M. Wunderlich, et al. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.
27. Mertz, J. A., A. R. Conery, B. M. Bryant, P. Sandy, S. Balasubramanian, D. A. Mele, L. Bergeron, and R. J. Sims, III. 2011. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 108: 16669-16674.
28. Belkina, A. C., and G. V. Denis. 2012. BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer 12: 465-477.
29. Gyuris, A., D. J. Donovan, K. A. Seymour, L. A. Lovasco, N. R. Smilowitz, A. L. P. Halperin, J. E. Klysik, and R. N. Freiman. 2009. The chromatin-targeting protein Brd2 is required for neural tube closure and embryogenesis. Biochim. Biophys. Acta 1789: 413-421.
30. Shang, E., X. Wang, D. Wen, D. A. Greenberg, and D. J. Wolgemuth. 2009. Double bromodomain-containing gene Brd2 is essential for embryonic development in mouse. Dev. Dyn. 238: 908-917.
31. Houzelstein, D., S. L. Bullock, D. E. Lynch, E. F. Grigorieva, V. A. Wilson, and R. S. P. Beddington. 2002. Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. Mol. Cell. Biol. 22: 3794-3802.
32. Xu, H., G. T. Barnes, Q. Yang, G. Tan, D. Yang, C. J. Chou, J. Sole, A. Nichols, J. S. Ross, L. A. Tartaglia, and H. Chen. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112: 1821-1830.
33. Shoelson, S. E., J. Lee, and A. B. Goldfine. 2006. Inflammation and insulin resistance. J. Clin. Invest. 116: 1793-1801.
34. Magness, S. T., H. Jijon, N. Van Houten Fisher, N. E. Sharpless, D. A. Brenner, and C. Jobin. 2004. In vivo pattern of lipopolysaccharide and anti-CD3-induced NF-kappa B activation using a novel gene-targeted enhanced GFP reporter gene mouse. J. Immunol. 173: 1561-1570.
35. McCarthy, K. M., D. McDevit, A. Andreucci, R. Reeves, and B. S. Nikolajczyk. 2003. HMGA1 co-activates transcription in B cells through indirect association with DNA. J. Biol. Chem. 278: 42106-42114.
36. De Filippo, K., R. B. Henderson, M. Laschinger, and N. Hogg. 2008. Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. J. Immunol. 180: 4308-4315.
37. Kim, H. Y., H. K. Kim, J. R. Kim, and H. S. Kim. 2005. Upregulation of LPSinduced chemokine KC expression by 15-deoxy-delta12,14-prostaglandin J2 in mouse peritoneal macrophages. Immunol. Cell Biol. 83: 286-293.
38. Watanabe, H., K. Numata, T. Ito, K. Takagi, and A. Matsukawa. 2004. Innate immune response in Th1- and Th2-dominant mouse strains. Shock 22: 460-466.
39. Mills, C. D., K. Kincaid, J. M. Alt, M. J. Heilman, and A. M. Hill. 2000. M-1/M- 2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164: 6166-6173.
40. El Chartouni, C., and M. Rehli. 2010. Comprehensive analysis of TLR4-induced transcriptional responses in interleukin 4-primed mouse macrophages. Immunobiology 215: 780-787.
41. Schroder, K., P. J. Hertzog, T. Ravasi, and D. A. Hume. 2004. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75: 163-189.
42. Nakamura, Y., T. Umehara, K. Nakano, M. K. Jang, M. Shirouzu, S. Morita, H. Uda-Tochio, H. Hamana, T. Terada, N. Adachi, et al. 2007. Crystal structure of the human BRD2 bromodomain: insights into dimerization and recognition of acetylated histone H4. J. Biol. Chem. 282: 4193-4201.
43. López-Bojórquez, L. N., A. Z. Dehesa, and G. Reyes-Terán. 2004. Molecular mechanisms involved in the pathogenesis of septic shock. Arch. Med. Res. 35: 465-479.
44. Huang, B., X.-D. Yang, M.-M. Zhou, K. Ozato, and L.-F. Chen. 2009. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol. Cell. Biol. 29: 1375-1387.
45. Nicodeme, E., K. L. Jeffrey, U. Schaefer, S. Beinke, S. Dewell, C.-W. Chung, R. Chandwani, I. Marazzi, P. Wilson, H. Coste, et al. 2010. Suppression of inflammation by a synthetic histone mimic. Nature 468: 1119-1123.
46. Remick, D. G., D. E. Newcomb, G. L. Bolgos, and D. R. Call. 2000. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13: 110-116.
47. Juskewitch, J. E., B. E. Knudsen, J. L. Platt, K. A. Nath, K. L. Knutson, G. J. Brunn, and J. P. Grande. 2012. LPS-induced murine systemic inflammation is driven by parenchymal cell activation and exclusively predicted by early MCP-1 plasma levels. Am. J. Pathol. 180: 32-40.
48. Rittirsch, D., L. M. Hoesel, and P. A. Ward. 2007. The disconnect between animal models of sepsis and human sepsis. J. Leukoc. Biol. 81: 137-143.
49. Oberholzer, A., S. M. Souza, S. K. Tschoeke, C. Oberholzer, A. Abouhamze, J. P. Pribble, and L. L. Moldawer. 2005. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 23: 488-493.
50. Marshall, J. C. 2008. Sepsis: rethinking the approach to clinical research. J. Leukoc. Biol. 83: 471-482.
51. Ward, P. A., and M. Bosmann. 2012. A historical perspective on sepsis. Am. J. Pathol. 181: 2-7.